Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

View Full Paper
Ask AI
Bookmark
Share

Authors

DPDominic PizzarellaAKAmanda KofidesNTNickolas Tsakmaklis

Discussion

Loading...

Member takes

Overview

Analysis reveals myeloid-derived suppressor cells in bone marrow of WM patients, indicating BTK targeting potential for therapy.

Key Points

  • This study investigates the role of LOX1 in identifying PMN-MDSC in the bone marrow of WM patients.
  • Characterized polymorphonuclear-MDSC and monocytic-MDSC using spectral flow cytometry on BM and PB samples from WM patients.
  • Assessed inflammatory mediators including S100A8 and S100A9 in patient samples.
  • Analyzed transcriptional regulation of inflammatory genes using qRT-PCR in WM-related cell lines.
  • PMN-MDSC showed greater expression of LOX1 in untreated WM compared to healthy controls.
  • Constitutive activation of p-BTK in LOX1+ PMN-MDSC was observed across analyzed WM samples.
  • Upregulation of IL-6 and CXCL13 was noted in WM cells contextually linked with MYD88 variants.

Cite This Study

Pizzarella et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d667https://doi.org/10.1182/blood-2025-5731
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Expanded tumor-associated polymorphonuclear Myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity2024
  2. 2Disruption of MYD88 Pathway Signaling Leads to Loss of Constitutive IRAK1, NF-κβ and JAK/STAT Signaling and Induces Apoptosis of Cells Expressing the MYD88 L265P Mutation in Waldenstrom's Macroglobulinemia2011 · 4 citations
  3. 3The effects of bruton tyrosine kinase inhibitors on the waldenstrom macroglobulinemia microenvironment2025
  4. 4Genetic evolution of Waldenström macroglobulinemia across disease stages2025
  5. 5Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era2025